Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Company news > 2017

Company news, 2017

Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS
Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS
Active Biotech (Nasdaq Stockholm.
ChemDiv, Context Therapeutics and Torrey Pines Investment Announce CNS Co-Development Agreement
ChemDiv, Context Therapeutics and Torrey Pines Investment Announce CNS Co-Development Agreement
- Sigma1 is a high-value oncology and neurodegenerative disease target- Together, the partners will run the first ever high-throughput Sigma1 screenSAN DIEGO, Nov.
ChemDiv’s Discovery Chemistry Platform to Help Advance Tri-Institutional Therapeutics Discovery Institute Programs
ChemDiv’s Discovery Chemistry Platform to Help Advance Tri-Institutional Therapeutics Discovery Institute Programs
SAN DIEGO, CA, November 6, 2017 – ChemDiv Inc.
Nature Communications Publishes a Study that Identified Small Molecule Which Imposes Metabolic Stress and Cellular Death in Malignant Cells
Nature Communications Publishes a Study that Identified Small Molecule Which Imposes Metabolic Stress and Cellular Death in Malignant Cells
On October 16, 2017 NATURE COMMUNICATIONS published an article named «A novel Fer/FerT targeting compound selectively evokes metabolic stress and necrotic death in malignant cells.
ChemDiv Achieves Milestone in Viriom Collaboration on Elsulfavirine/VM1500A Long Acting Injectable Formulation Development
ChemDiv Achieves Milestone in Viriom Collaboration on Elsulfavirine/VM1500A Long Acting Injectable Formulation Development
ChemDiv has reached a development milestone in partnership with Viriom Inc.
ChemDiv to Help Afraxis Advance Synaptic Profiling Platform for CNS Drug Discovery
ChemDiv to Help Afraxis Advance Synaptic Profiling Platform for CNS Drug Discovery
SAN DIEGO, October 5, 2017 – ChemDiv Inc.
ChemDiv’s Executive Director Delivers Two Lectures on Drug Discovery in China
ChemDiv’s Executive Director Delivers Two Lectures on Drug Discovery in China
SAN DIEGO, October 2nd, 2017 – Sergey Bugrov, Executive Director of Global Discovery at ChemDiv, delivered two lectures entitled “Diverse Discovery Libraries and How They Can be Used in Researchâ€...
ChemDiv Successfully Achieves Milestone in Discovery Chemistry Collaboration with UC Davis Professor Gino Cortopassi
ChemDiv Successfully Achieves Milestone in Discovery Chemistry Collaboration with UC Davis Professor Gino Cortopassi
SAN DIEGO, September 29, 2017 – ChemDiv Inc.
ChemDiv Announces Multi-Year Hit Identification Collaboration with Janssen
ChemDiv Announces Multi-Year Hit Identification Collaboration with Janssen
SAN DIEGO, Jan.
ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection
ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection
SAN DIEGO, CA, June 09, 2017 – ChemDiv Inc.
Regen BioPharma Begins Optimization of NR2F6 Small Molecule Modulators
Regen BioPharma Begins Optimization of NR2F6 Small Molecule Modulators
SAN DIEGO, February 1, 2017 /PRNewswire/ --ChemDiv Inc.
ChemDiv Reaches Milestone in Viriom Collaboration
ChemDiv Reaches Milestone in Viriom Collaboration
ChemDiv has reached a development milestone in partnership with Viriom Inc.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand